课题基金 / 基金详情

Omics Technology facility

Omics Technology facility
组学技术设施
批准号:
10703083
负责人:
Liang Cao
金额:
$82.28万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Liang Cao的其他基金

相似基金

相关文献

中文摘要
翻译
由于该项目是在本财政年度开始的,主要努力集中在建立业务和开发核心技术上。答:团队组建:1.网络实验室:在22财年4月,又有两名成员从之前的分子概况/临床组学核心部门调到我们这里,其中一名成员于6月22日离开了NCI。我们将在2013财年填补这一空缺职位。2.IT团队:通过NCI Frederick承包商招募了两名IT团队成员。该IT团队目前正在帮助建立用于下一代测序(NGS)数据分析的管道。B.核心技术开发。我们主要致力于建立基于NGS的技术,以发现癌症驱动因素,并了解生物学机制。具体地说,以下技术已经建立或即将建立。1.用于癌症突变检测的NGS。我们采用了DNA和RNA外显子组测序的方法,目的是检测SNV、缺失和插入。2.NGS用于表达和融合检测。实验室的工作人员接受了RNA外显子序列的培训,以检测融合和进行表达分析。3.表观遗传调控。我们采用了两种不同的CHIP-SEQ方法,包括抗体介导的微球菌核酸酶切割DNA和转座。4.癌症基因面板的定向测序5.针对肿瘤抗原的T细胞介导反应中涉及的基因的定制分析开发和测序6.验证NGS方法的预期研究或临床应用,7.完善用于NGS数据分析的分析管道
英文摘要
As the project was started in this fiscal year, the main effort was focused on the establishment of operation and in the development of core technologies. A. Team formation: 1. Web lab: Two additional members were transferred to us in April of FY22 from the previous Molecular Profile/Clinomics Core, one of which had since left NCI in June 22. We'll fill in this vacate position in FY23. 2. IT team: Two members were recruited to the IT team via the NCI Frederick contractor. This IT team is currently helping to establish the pipelines for Next Generation Sequencing (NGS) data analysis. B. Core technology development. We are mainly focused on establishing NGS-based technologies for discovery cancer drivers, and for understanding biological mechanisms. Specifically, the following technologies are established or near establishment. 1. NGS for cancer mutation detection. We adapted methods for both DNA and RNA Exome sequencing aimed for detection SNV, deletion, an insertion. 2. NGS for expression and fusion detection. The staff in the lab were trained for RNA Exome seq for the detection of fusions, and for expression analysis. 3. Epigenetic regulation. We adapted two different methods for chip-seq, including antibody-mediated DNA cutting by micrococcal nucleases and transposes. 4. Targeted sequencing of cancer gene panels 5. Customized assay development and sequencing of genes involved in T-cell mediated responses against tumor antigens 6. Validation of the NGS methods for their intended research or clinical use, respectively 7. Refining the analytical pipelines for NGS data analysis
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical Development of Novel Targeted Therapeutics Against Pediatric Sarcoma
Molecular Pathogenic Mechanism of Rhabdomyosarcoma
Biomarker Investigations for Clinical Trials
Omics Technology facility
海外基金